Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513550 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,257
- Enrollment target
NCT02513550 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,257 participants.
The verdict
NCT02513550, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,257 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,257 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513550
The ClinicalTrials.gov registry entry for NCT02513550 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02513550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513550 about?
NCT02513550 is a clinical study titled "A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis". The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
What is the current status of trial NCT02513550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,257 participants. The study started on 2015-08. Estimated completion is 2017-08-03.
What interventions are being tested in trial NCT02513550?
The interventions under investigation include: Placebo (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT02513550?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.